Syndax Pharmaceuticals, Inc. (SNDX)
SNDX moved a median of +0.04% 30 minutes after news, and +0.48% by the close. How SNDX actually reacts to news — the realized, point-in-time move the market made, measured across 306 labeled events over the last three years with zero look-ahead.
SNDX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 304 |
| 30-min | +0.04% | 51% | 306 |
| 60-min | +0.08% | 52% | 306 |
| to close | +0.48% | 55% | 303 |
| Middle 50% of SNDX reactions | -1.07% to +1.19% |
|---|---|
| Median reaction (30-min) | +0.04% |
| Measured reactions | 306 |
Half of all Syndax Pharmaceuticals, Inc. news events land between -1.07% and +1.19% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SNDX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.78% | 36% | -1.40% |
| Coverage initiations | 24 | -0.49% | 29% | -0.73% |
| Rating reiterations | 95 | -0.24% | 42% | -0.28% |
| Price-target raises | 29 | -0.04% | 48% | -0.20% |
| Price-target cuts | 14 | +0.21% | 50% | -0.32% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how SNDX ranks against every other measured name →
That’s how SNDX usually reacts — get an email when it moves on news →Email me when SNDX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SNDX's baseline. Nothing else.
Recent SNDX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List | Press release | GlobeNewswire | — | — | |
| Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | -2.26% | -4.52% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.17% | +1.42% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.14% | -1.24% | |
| Syndax Announces Participation in September Investor Conferences | Press release | GlobeNewswire | +0.47% | +4.20% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.38% | +0.77% | |
| Form 10-Q Syndax Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +9.13% | +15.81% | |
| Form 8-K Syndax Pharmaceuticals For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +9.13% | +15.81% | |
| Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +9.13% | +15.81% | |
| Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 | Press release | GlobeNewswire | -1.17% | -4.15% | |
| Form 8-K Syndax Pharmaceuticals For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +5.42% | |
| Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event | Press release | GlobeNewswire | -0.17% | +5.42% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.67% | +4.20% | |
| Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology | Press release | GlobeNewswire | +0.91% | +3.47% | |
| Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 | Press release | GlobeNewswire | +0.91% | +3.47% | |
| Form 8-K Syndax Pharmaceuticals For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +3.47% | |
| Form 8-K Syndax Pharmaceuticals For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | +5.38% | |
| Form DEFA14A Syndax Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -0.06% | +5.38% | |
| Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes | Press release | GlobeNewswire | -0.06% | +5.38% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.11% | -4.36% | |
| Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data | Press release | GlobeNewswire | -0.92% | -1.29% | |
| Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 | Press release | GlobeNewswire | +0.31% | -2.08% | |
| Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data | Press release | GlobeNewswire | +1.42% | +0.81% | |
| Syndax Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.60% | +3.76% | |
| Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition | Press release | GlobeNewswire | -0.14% | -2.11% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.22% | -0.82% | |
| Form 10-Q Syndax Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.26% | -9.86% | |
| Form 8-K Syndax Pharmaceuticals For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -2.26% | -9.86% | |
| Form ARS Syndax Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.26% | -9.86% | |
| Form DEF 14A Syndax Pharmaceuticals For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | -2.26% | -9.86% | |
| Form DEFA14A Syndax Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -2.26% | -9.86% | |
| Syndax Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.26% | -9.86% | |
| Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 | Press release | GlobeNewswire | -0.64% | +1.52% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.04% | -3.15% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.19% | +1.27% | |
| Form 10-K Syndax Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.05% | +9.76% | |
| Form 8-K Syndax Pharmaceuticals For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | +9.76% | |
| Form S-8 Syndax Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | -0.05% | +9.76% | |
| Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.05% | +9.76% | |
| Syndax Announces Participation in March Investor Conferences | Press release | GlobeNewswire | +2.27% | +0.30% | |
| Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 | Press release | GlobeNewswire | -0.44% | +1.78% | |
| Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit | Press release | GlobeNewswire | +0.98% | -1.66% | |
| Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.98% | -1.66% | |
| Form 8-K Syndax Pharmaceuticals For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | +0.64% | |
| Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.10% | -1.33% | |
| Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. | Press release | GlobeNewswire | +2.70% | +8.49% | |
| Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.28% | -5.29% | |
| Form 8-K Syndax Pharmaceuticals For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | +4.68% | |
| Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025 | Press release | GlobeNewswire | -0.54% | +0.29% | |
| Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum | Press release | GlobeNewswire | -1.94% | -1.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SNDX section they belong to.
Where else SNDX is measured.
SNDX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Adverum Biotechnologies, Inc. (ADVM) | 306 | 0.00% | 49% |
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 305 | +0.42% | 53% |
| U.S. Physical Therapy, Inc. (USPH) | 304 | -0.03% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Syndax Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled SNDX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 306 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of SNDX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SNDX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.